India FSSAI Nutraceutical Readiness: 2022 Amendments, the Health Supplements Schedule and the FSS Act Licensing Path

The 2016 Regulations carve seven categories under the FSS Act: Health Supplements, Nutraceuticals, Foods for Special Dietary Use (FSDU), Foods for Special Medical Purpose (FSMP), Specialty Food containing Plant or Botanical Ingredients, Foods containing Probiotic Ingredients, and Foods containing Prebiotic Ingredients. Health Supplements deliver nutrients for healthy individuals to supplement the diet. Nutraceuticals deliver isolated or concentrated substances with physiological or beneficial effects beyond basic nutrition. The category choice is regulatory — Nutraceuticals are held to a higher ingredient-purity and dose-evidence bar than Health Supplements, and the label must declare the category. Misclassification (selling a Nutraceutical as a Health Supplement to dodge the higher bar, or vice versa) is the most common FSSAI compliance finding on imported lines.

The 2022 amendment substantially tightened Schedule I (vitamins and minerals with RDA-based dose limits), Schedule II (essential amino acids), Schedule IV (plant or botanical ingredients with monograph references — Indian Pharmacopoeia, USP, EP, Ayurvedic Pharmacopoeia, BP), Schedule VI (probiotic strains with deposit numbers in recognised culture collections), Schedule VII (prebiotic ingredients) and Schedule VIII (other novel substances). The 2024 amendment removed the contentious requirement to declare added flavouring beyond regulatory thresholds and refined the front-of-pack labelling for high-fat/sugar/salt products. The framework distinguishes synthetic from natural sources for several ingredients (notably vitamin E, beta-carotene, omega-3s) — the source restriction sits on the schedule and changing source mid-shelf-life invalidates the licence.

Every nutraceutical or health supplement business with turnover above the small-business threshold needs an FSSAI Central Licence (FoSCoS, the Food Safety Compliance System portal). The licence is granted to the manufacturer, importer or both. Pre-market Product Approval through the Product Approval Branch is separately required when (1) an ingredient is not on any FSSAI Schedule and is therefore novel, (2) a claim falls outside the closed FSS Advertisement and Claims Regulations 2018 list, or (3) the product is FSMP for a specific medical condition. Product Approval is a multi-month scientific evaluation. A product that fits every Schedule with allowed claims and dose runs on the Central Licence alone.

Indian supplement labels are governed by FSS (Labelling and Display) Regulations 2020. Mandatory: product name with the regulatory category, ingredient list, nutritional information per serving, allergen declaration, manufacturer/importer/packer with FSSAI licence number prefixed with the FSSAI logo, country of origin for imports, lot number, manufacture and expiry/best-before dates, and the consumer complaint contact. For nutraceuticals and health supplements: the mandatory warnings 'Not for medicinal use' and 'Not recommended for children, pregnant women, lactating mothers' (or as applicable based on the safety profile), plus 'Read the label carefully before use'. Languages: English plus Hindi or one regional language (state-distribution-dependent). Front-of-pack labelling for HFSS (high fat/sugar/salt) products is being phased in.

Days 1–20: category decision (Health Supplement vs Nutraceutical), Schedule gate per ingredient, claim scrub against FSS Advertisement and Claims Regulations 2018. Days 21–40: importer setup, FoSCoS Central Licence application for the importer. Days 41–70: label build (English + Hindi/regional), nutritional table, mandatory warnings, FSSAI logo placement. Days 71–100: licence grant, manufacturer GMP evidence acceptance, customs clearance procedure setup with FSSAI clearance at port. Days 101–130: first shipment, FSSAI port-of-entry sampling, distributor onboarding. Days 131–150: post-market — adverse event reporting setup, FSSAI surveillance response readiness.